Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is expected to exhibit a CAGR of 38.6% and valued at US$ 290.8 million in 2028 | Teva Pharmaceutical Industries Ltd., AbbVie, Inc

Overview:

Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare inherited condition in which the bile salt exporter pump is mutated. In this disease, bile acid is not released from the liver. This causes episodes of cholestasis. Usually, these episodes resolve on their own and do not cause any liver damage. However, in cases where a pregnant woman develops this disorder, there is a greater risk of stillbirth or premature delivery. Although this disease is usually not fatal, patients must undergo surgery to remove the damaged organ. This disease results from a defective gene that affects the ABCB11 gene on chromosome 2q31. Symptoms of PFIC2 include atrophic liver and non-specific giant cell hepatitis. The exact gene mutation causes PFIC2 varies from patient to patient.

LIMITED TIME OFFER – Hurry Up!!!
Buy Now To Avail Flat 30% Off

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4399

Market Dynamics:

Increasing approvals of drugs from regulatory organizations is expected to propel growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. For instance, in July 2021, the U.S. FDA granted approval to Albireo Pharma Inc. for odevixibat (Bylvay) for the treatment of pruritus in every subtypes of progressive familial intrahepatic cholestasis.

However, increasing requirement of new therapies for the treatment of PFIC type 2 is expected to hinder growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period.

Impact of COVID-19:

The global progressive familial intrahepatic cholestasis type 2 treatment market witnessed a moderate impact of COVID-19 pandemic. The patients with PFIC type 2 received extra care during the pandemic as the liver conditions can become complicated during the COVID-19 infection. Due to the outbreak of COVID-19 virus many countries implemented strict lockdown regulations. Increasing cases of COVID-19 infections created shortage of beds in hospitals, which resulted into suspension of several liver transplant procedures.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4399

Key Takeaways:

• The global progressive familial intrahepatic cholestasis type 2 treatment market is expected to expand, exhibiting a CAGR of 38.6% during the forecast period due growing R&D of new drugs for the PFIC type 2 treatment. For instance, in December 2021, Mirum Pharmaceuticals Inc. presented new studies from LIVMARLI (maralixibat) oral solution clinical studies for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis type 2, at North American Society for Pediatric Gastroenterology Hepatology and Nutrition Annual Meeting.
• North America is projected to witness strong growth in the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. This is attributed to increasing clinical trials intervention for treatment of the PFIC type 2 in this geography.
• Major players functioning in the global progressive familial intrahepatic cholestasis type 2 treatment market are Albireo Pharma, Inc., Novartis International AG, Mylan Pharmaceuticals, Inc., Sanofi S.A., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Akorn, Inc., Mirum Pharmaceuticals, Par Pharmaceuticals, Inc., and AbbVie, Inc.

Reasons to Purchase This Report

• Current and future of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4399

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Overview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Drivers
   • Restraints
   • Market Opportunities
   • Impact Analysis
   • Key Developments
   • Regulatory Scenario
   • PEST Analysis
   • Pipeline Analysis
   • Epidemiology
   • Diagnosis and Treatment Overview
   • Prescription Pattern
   • Physicians Preferences and Views
4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
   
   • Impact on Supply Chain of Pharmaceutical Industry
   • Impact on PFIC Type 2 Patients
5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market , By Drug, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Ursodeoxycholic acid
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Cholestyramine
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Rifampicin
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Late Stage Pipeline Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, By Region, 2017 – 2027
     • Regional Trends
   • North America
     • Market Size and Forecast, By Drug, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • U.S.
       • Canada
   • Europe
     • U.K.
     • Germany
     • Italy
     • France
     • Spain
     • Russia
     • Rest of Europe
   • Asia Pacific
     • China
     • Japan
     • India
     • ASEAN
     • Australia
     • South Korea
     • Rest of Asia Pacific
   • Latin America
     • Brazil
     • Mexico
     • Argentina
     • Rest of Latin America
   • Middle East
     • GCC
     • Israel
     • Rest of Middle East
   • Africa
     • North Africa
     • Central Africa
     • South Africa